MAKING SCIENCE GROUP, SA (the "Company") under the provisions of article 17 of Regulation (EU) No. 596/2014 on market abuse and article 228 of the consolidated text of the Securities Market Law, approved by Royal Legislative Decree 4/2015, of October 23, and concordant provisions, as well as in the concordant provisions, as well as in Circular 3/2020 of the BME Growth segment of BME MTF Equity, states The following is known:

OTHER RELEVANT INFORMATION

In Madrid, on February 22, 2021, at 9:00 a.m., an Extraordinary General Meeting of shareholders of the Company was held at the registered office, with an attendance of 77.75% of the share capital of the Company with voting rights.

In said session, the items on the agenda of the call published on January 20, 2022 on the BME Growth website as well as on the Company's website as "Other Relevant Information" were submitted for deliberation by the attendees. the following resolutions having been adopted unanimously by the attendees:

1. Authorization to the Board of Directors, in accordance with the provisions of article 297.1 b) of the Capital Companies Act, to increase the share capital through monetary contributions up to the limit of 20% of the amount of the share capital, within a maximum period of 5 years, in one or several times, and in the opportunity and amount that it considers appropriate. Within the maximum amount indicated, the Board of Directors is empowered to exclude the preferential subscription right up to the aforementioned maximum limit of 20% of the share capital.

2. Delegation of powers.

3. Drafting, reading and approval of the minutes of the meeting.

In compliance with the provisions of Circular 3/2020 of the BME MTF Equity, it is expressly stated that the information communicated hereby has been prepared under the exclusive responsibility of the Company and its administrators with current positions.

Sincerely,
Managing Director of Making Science Group, SA
José Antonio Martínez Aguilar